CXCR4 and Hepatic fibrosis: In addition, studies have also shown that CXCR4 expression could be induced in activated hepatic stellate cells (HSCs) during the progression of liver fibrosis, and CXCR4-targeted nanoparticles combined with sorafenib and MEK inhibitors could reduce liver fibrosis and prevent HCC development 26, 27.